Hims & Hers to stop advertising compounded GLP-1s and sell branded Ozempic and Wegovy
The deal moves a major telehealth platform from compounded semaglutide to FDA-approved Ozempic and Wegovy, leaving unclear what patients who used compounded versions will pay.
Novo Nordisk and the telehealth company Hims & Hers announced on March 9, 2026 that they resolved their dispute, with Hims & Hers agreeing to stop advertising compounded GLP-1 drugs and to offer Novo Nordisk's branded semaglutide products instead [1][2]. Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers as part of the agreement, but reserved the right to refile it [1][2].
Under the deal, Hims & Hers will offer Ozempic (semaglutide) injection in 0.5 mg, 1 mg and 2 mg doses, and Wegovy (semaglutide) as an injection in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg doses and as a 25 mg oral tablet, at Novo Nordisk's established self-pay prices [2]. The company will stop advertising compounded GLP-1 products on its platform and in its marketing materials, with an exception for cases described as medically necessary [1][2]. Existing patients using compounded semaglutide will have the opportunity to transition to FDA-approved alternatives when clinically appropriate and in consultation with a licensed health care professional [2]. Novo Nordisk called the shift a "meaningful win for patients" [2].
Whether Hims & Hers may continue to supply compounded semaglutide to an individual patient whose clinical needs a branded product cannot meet has not been disclosed. The announced terms describe only the "medically necessary" exception to the advertising halt [1].
Ozempic is approved for adults with type 2 diabetes to improve blood sugar control and to reduce the risk of major cardiovascular events in those with established cardiovascular disease. Wegovy is approved, along with diet and exercise, for chronic weight management and to reduce that cardiovascular risk in adults with overweight or obesity and established cardiovascular disease [2].
The agreement follows months of escalating federal enforcement. FDA Commissioner Martin A. Makary said in a February 6, 2026 statement that the agency cannot verify the "quality, safety, or efficacy" of compounded products mass-marketed as alternatives to approved drugs, and that it would use enforcement tools including seizure and injunction against companies that do not fix violations [2].
On February 20, 2026, the FDA sent 30 warning letters to telehealth companies and online wellness clinics over allegedly false or misleading claims about compounded GLP-1s; the letters were made public on March 3 [1]. Announcing them, Makary said, "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action." [1] The agency had earlier sent about 100 cease-and-desist letters, in September 2025, over compounded drug advertising [1].
Not everyone agrees with the agency's framing. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, said he was "puzzled" by Makary's suggestion that the scale of compounders' marketing, rather than only its truthfulness, was part of the problem. Brunner said the Supreme Court has made clear that "lawful pharmacies cannot be broadly prohibited from communicating truthful information about their services." [1]
Why it matters for patients
Compounded drugs are not FDA-approved and have not gone through the clinical testing required for approval. They are intended to fill specific gaps, such as a verified drug shortage or an individual patient's needs [1]. The FDA lifted the shortage designation for tirzepatide in late 2024, and semaglutide had already come off the shortage list, so the shortage justification for large-scale compounding of these drugs no longer applied [1]. Compounded versions have often sold for a fraction of the price of branded products [1].
For patients receiving compounded semaglutide through Hims & Hers, the announced plan is a move to branded products at Novo Nordisk's self-pay prices [2]. The dollar amounts of those self-pay prices have not been disclosed, and it is not yet known how patients' insurance will treat the branded products. The FDA also says companies may not promote compounded drugs as generic equivalents of approved products, claim they contain the same active ingredient, or say they are clinically proven to produce comparable results [2].
What happens next
Recipients of the February warning letters were required to respond within 15 working days to the FDA's Office of Compliance, describing corrective steps such as identifying compounding sources and removing misleading website claims. Companies that do not respond face possible seizure or injunction "without further notice," the agency said [1]. Novo Nordisk has reserved the right to refile its patent lawsuit against Hims & Hers [1][2]. Whether the arrangement becomes a model for other telehealth companies remains to be seen [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.